Nexavar
Nexavar or Sorafenib stops the growth of metastatic thyroid cancer by nearly 5 months - Jellypharmacy.com - If the FDA (Food and Drug Administration) approves liver and kidney cancer drug Nexavar it would be the first effective agent for the use in radioactive iodine-refractory differentiated thyroid cancer. » By Wilson Martin, created on Jul. 20 2013 In Press Releases and Company Profiles |